Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.

PMID: 36206609
Journal: BREAST
Year: 2022
Reference: Breast. 2022 Dec;66:77-84. doi: 10.1016/j.breast.2022.09.006. Epub 2022 Sep 28.
Impact factor:
Publication type: Paper in international publication
Authors: Alvarez Lopez, Isabel Manuela; Anton Torres, Antonio; Barnadas Molins, Agusti; Bellet Ezquerra, Meritxell; Cantos Sanchez de Ibarguen, Blanca; Ciruelos Gil, Eva Maria; de Casa, Sonia; De la Cruz Merino, Luis; De la Haba-Rodriguez, Juan; de Toro Salas, Ruben et al.
DOI: 10.1016/j.breast.2022.09.006

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

PMID: 35793454
Journal: Blood Advances
Year: 2022
Reference: Blood Adv. 2022 Jun 24. pii: 485692. doi: 10.1182/bloodadvances.2022007776.
Impact factor: 6.799
Publication type: Paper in international publication
Authors: Subklewe, Marion; Barba, Pere; Bachy, Emmanuel; von Bergwelt-Baildon, Michael; Sohlbach, Kristina; Schmidt, Christian; Blumenberg, Viktoria; Schafer, Jonas A; Naumann, Ralph; Hernani, Rafael et al.
DOI: 10.1182/bloodadvances.2022007776

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

PMID: 35793454
Journal: Blood Advances
Year: 2022
Reference: Blood Adv. 2022 Aug 23;6(16):4719-4725. doi: 10.1182/bloodadvances.2022007776.
Impact factor:
Publication type: Paper in international publication
Authors: Bachy, Emmanuel; Barba, Pere; Blumenberg, Viktoria; Buecklein, Veit; Burchert, Andreas; Fransecky, Lars; Hernani, Rafael; Iacoboni, Gloria; Naumann, Ralph; Rejeski, Kai et al.
DOI: 10.1182/bloodadvances.2022007776

Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study.

PMID: 34788858
Journal: NEPHROLOGY DIALYSIS TRANSPLANTATION
Year: 2022
Reference: Nephrol Dial Transplant. 2022 Sep 22;37(10):1868-1878. doi: 10.1093/ndt/gfab313.
Impact factor:
Publication type: Paper in international publication
Authors: Carnerero, Manuel; Cervera, Maria Cinta Aguilar; de Sequera, Patricia; Gansevoort, Ron T; Gracia-Iguacel, Carolina; Lara, Noelia Balibrea; Leyva, Alba; Mantecon, Carlos Jesus Jarava; Marquez, Maria Gabriela Sanchez; Millan, Juan Carlos Ruiz San et al.
DOI: 10.1093/ndt/gfab313

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.

PMID: 35397434
Journal: ESMO Open
Year: 2022
Reference: ESMO Open. 2022 Apr;7(2):100447. doi: 10.1016/j.esmoop.2022.100447. Epub 2022 Apr 6.
Impact factor: 6.54
Publication type: Paper in international publication
Authors: Ochsenreither, S, Fiedler, W M, Conte, G D, Macchini, M, Matos, I, Habel, B, Ahrens-Fath, I, Raspagliesi, F, Keilholz, U, Rolling, C et al.
DOI: 10.1016/j.esmoop.2022.100447

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.

PMID: 35397434
Journal: ESMO Open
Year: 2022
Reference: ESMO Open. 2022 Apr;7(2):100447. doi: 10.1016/j.esmoop.2022.100447. Epub 2022 Apr 6.
Impact factor:
Publication type: Paper in international publication
Authors: Ahrens-Fath, I; Baumeister, H; Conte, G D; Fiedler, W M; Garralda, E; Habel, B; Kebenko, M; Keilholz, U; Klinghammer, K F; Lorusso, D et al.
DOI: 10.1016/j.esmoop.2022.100447

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.

PMID: 36380312
Journal: CRITICAL CARE
Year: 2022
Reference: Crit Care. 2022 Nov 15;26(1):355. doi: 10.1186/s13054-022-04204-9.
Impact factor:
Publication type: Paper in international publication
Authors: Akhgar, Ahmad; Akova, Murat; Ali, Omar; Annane, Djillali; Barraud, Olivier; Bellamy, Terramika; Bonten, Marc; Bourgeois, Marc; Canas, Borja Suberviola; Carmeli, Yehuda et al.
DOI: 10.1186/s13054-022-04204-9

Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study.

PMID: 35885517
Journal: Diagnostics
Year: 2022
Reference: Diagnostics (Basel). 2022 Jul 1;12(7). pii: diagnostics12071612. doi: 10.3390/diagnostics12071612.
Impact factor:
Publication type: Paper in international publication
Authors: Aguilera, Cristina; Agusti, Antonia; Bosch, Montserrat; Campos-Varela, Isabel; Cereza, Gloria; Danes, Immaculada; Guillen, Elena; Mestre-Torres, Jaume; Miarons, Marta; Sanchez-Montalva, Adrian et al.
DOI: 10.3390/diagnostics12071612

Safety of Obtaining an Extra Biobank Kidney Biopsy Core.

PMID: 35268550
Journal: Journal of Clinical Medicine
Year: 2022
Reference: J Clin Med. 2022 Mar 7;11(5). pii: jcm11051459. doi: 10.3390/jcm11051459.
Impact factor: 4.242
Publication type: Paper in international publication
Authors: Mast, Richard, Vergara, Ander, Agraz, Irene, Leon, Juan Carlos, Bolufer, Monica, Gabaldon, Maria-Alejandra, Seron, Daniel, Bestard, Oriol, Soler, Maria Jose, Garcia-Carro, Clara et al.
DOI: 10.3390/jcm11051459

Safety of Obtaining an Extra Biobank Kidney Biopsy Core.

PMID: 35268550
Journal: Journal of Clinical Medicine
Year: 2022
Reference: J Clin Med. 2022 Mar 7;11(5). pii: jcm11051459. doi: 10.3390/jcm11051459.
Impact factor:
Publication type: Paper in international publication
Authors: Agraz, Irene; Bermejo, Sheila; Bestard, Oriol; Bolufer, Monica; Gabaldon, Maria-Alejandra; Garcia-Carro, Clara; Leon, Juan Carlos; Mast, Richard; Seron, Daniel; Soler, Maria Jose et al.
DOI: 10.3390/jcm11051459

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial.

PMID: 36678638
Journal: Pharmaceutics
Year: 2022
Reference: Pharmaceutics. 2022 Dec 20;15(1):9. doi: 10.3390/pharmaceutics15010009.
Impact factor:
Publication type: Paper in international publication
Authors: Aguirre, Sarita; Akkerman, Onno W; Alffenaar, Jan-Willem C; Battaglia, Arturo; Espinosa-Pereiro, Juan; Ghimire, Samiksha; Magis-Escurra, Cecile; Molinas, Gladys; Sanchez-Montalva, Adrian; Sturkenboom, Marieke G G et al.
DOI: 10.3390/pharmaceutics15010009

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.

PMID: 35466070
Journal: Clinical Lung Cancer
Year: 2022
Reference: Clin Lung Cancer. 2022 Jun;23(4):320-332. doi: 10.1016/j.cllc.2022.03.002. Epub 2022 Mar 17.
Impact factor: 4.785
Publication type: Paper in international publication
Authors: Veillon, Remi, Sakai, Hiroshi, Le, Xiuning, Felip, Enriqueta, Cortot, Alexis B, Smit, Egbert F, Park, Keunchil, Griesinger, Frank, Britschgi, Christian, Wu, Yi-Long et al.
DOI: 10.1016/j.cllc.2022.03.002

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.

PMID: 35466070
Journal: Clinical Lung Cancer
Year: 2022
Reference: Clin Lung Cancer. 2022 Jun;23(4):320-332. doi: 10.1016/j.cllc.2022.03.002. Epub 2022 Mar 17.
Impact factor:
Publication type: Paper in international publication
Authors: Baijal, Shobhit; Berghoff, Karin; Britschgi, Christian; Cortot, Alexis B; Felip, Enriqueta; Griesinger, Frank; Jr, Gilberto de Castro; Le, Xiuning; Melosky, Barbara; Otto, Gordon et al.
DOI: 10.1016/j.cllc.2022.03.002

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, dose escalation study.

PMID: 34724226
Journal: INTERNATIONAL JOURNAL OF CANCER
Year: 2022
Reference: Int J Cancer. 2022 Mar 15;150(6):993-1006. doi: 10.1002/ijc.33861. Epub 2021 Nov 26.
Impact factor: 7.396
Publication type: Paper in international publication
Authors: Datta, Antara, Foley, Shawn W, McCabe, Michael T, Wu, Yuehui, Horner, Thierry, Kremer, Brandon E, Dhar, Arindam, O'Dwyer, Peter J, Shapiro, Geoffrey I, Piha-Paul, Sarina A et al.
DOI: 10.1002/ijc.33861

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, dose escalation study.

PMID: 34724226
Journal: INTERNATIONAL JOURNAL OF CANCER
Year: 2022
Reference: Int J Cancer. 2022 Mar 15;150(6):993-1006. doi: 10.1002/ijc.33861. Epub 2021 Nov 26.
Impact factor:
Publication type: Paper in international publication
Authors: Azad, Arun A; Blay, Jean-Yves; Brana Garcia, Irene; Cassier, Philippe A; Cousin, Sophie; Datta, Antara; de Bono, Johann S; Dhar, Arindam; Ferron-Brady, Geraldine; Foley, Shawn W et al.
DOI: 10.1002/ijc.33861

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study.

PMID: 35026412
Journal: ANNALS OF ONCOLOGY
Year: 2022
Reference: Ann Oncol. 2022 Apr;33(4):416-425. doi: 10.1016/j.annonc.2021.12.012. Epub 2022 Jan 10.
Impact factor: 32.976
Publication type: Paper in international publication
Authors: Gazzah, A, Bedard, P L, Hierro, C, Kang, Y-K, Abdul Razak, A, Ryu, M-H, Demers, B, Fagniez, N, Henry, C, Hospitel, M et al.
DOI: 10.1016/j.annonc.2021.12.012

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study.

PMID: 35026412
Journal: ANNALS OF ONCOLOGY
Year: 2022
Reference: Ann Oncol. 2022 Apr;33(4):416-425. doi: 10.1016/j.annonc.2021.12.012. Epub 2022 Jan 10.
Impact factor:
Publication type: Paper in international publication
Authors: Abdul Razak, A; Bedard, P L; Demers, B; Fagniez, N; Gazzah, A; Henry, C; Hierro, C; Hospitel, M; Kang, Y-K; Ryu, M-H et al.
DOI: 10.1016/j.annonc.2021.12.012

Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine.

PMID: 36054144
Journal: ANNALS OF NEUROLOGY
Year: 2022
Reference: Ann Neurol. 2022 Nov;92(5):846-859. doi: 10.1002/ana.26472. Epub 2022 Aug 24.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Asskour, Laila; Caronna, Edoardo; Gallardo, Victor J; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1002/ana.26472

Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.

PMID: 34601944
Journal: CEPHALALGIA
Year: 2022
Reference: Cephalalgia. 2022 Mar;42(3):186-196. doi: 10.1177/03331024211040467. Epub 2021 Oct 4.
Impact factor: 6.295
Publication type: Paper in international publication
Authors: Asskour, Laila, Caronna, Edoardo, Torres-Ferrus, Marta, Pozo-Rosich, Patricia, Gallardo, Victor J, Alpuente, Alicia et al.
DOI: 10.1177/03331024211040467

Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.

PMID: 34601944
Journal: CEPHALALGIA
Year: 2022
Reference: Cephalalgia. 2022 Mar;42(3):186-196. doi: 10.1177/03331024211040467. Epub 2021 Oct 4.
Impact factor:
Publication type: Paper in international publication
Authors: Alpuente, Alicia; Asskour, Laila; Caronna, Edoardo; Gallardo, Victor J; Pozo-Rosich, Patricia; Torres-Ferrus, Marta et al.
DOI: 10.1177/03331024211040467

Salvage hip replacement after cut-out failure of cephalomedullary nail fixation for proximal femur fractures: a case series describing the technique and results.

PMID: 35922520
Journal: INTERNATIONAL ORTHOPAEDICS
Year: 2022
Reference: Int Orthop. 2022 Dec;46(12):2775-2783. doi: 10.1007/s00264-022-05529-4. Epub 2022 Aug 4.
Impact factor:
Publication type: Paper in international publication
Authors: Andres-Peiro, Jose-Vicente; Corro, Sebastian; Garcia-Sanchez, Yaiza; Guerra-Farfan, Ernesto; Oleo-Taltavull, Rafael; Selga-Marsa, Jordi; Teixidor-Serra, Jordi; Tomas-Hernandez, Jordi et al.
DOI: 10.1007/s00264-022-05529-4

Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights.

PMID: 36539800
Journal: Trials
Year: 2022
Reference: Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4.
Impact factor:
Publication type: Review in international publication
Authors: Ballesteros, Monica; Fernandez-Felix, Borja M; Ferreira-Gonzalez, Ignacio; Herrador, Lorena; Lora, David; Lumbreras, Blanca; Marsal, Josep Ramon; Oristrell, Gerard; Osorio, Dimelza; Osorio, Dimelza et al.
DOI: 10.1186/s13063-022-06977-4

SARS CoV-2 seropositivity in haemodialysis patients.

PMID: 36828704
Journal: NEFROLOGIA
Year: 2022
Reference: Nefrologia (Engl Ed). 2022 Nov-Dec;42(6):733-736. doi: 10.1016/j.nefroe.2021.04.015. Epub 2023 Feb 20.
Impact factor:
Publication type: Letter or abstract
Authors: Azancot, Maria; Azancot, Maria; Castaneda, Zaira; Leon-Roman, Juan; Ramos, Natalia; Soler, Maria Jose; Toapanta, Nestor; Zuniga, Jose et al.
DOI: 10.1016/j.nefroe.2021.04.015

[SARS CoV-2 seropositivity in hemodialysis patients].

PMID: 34075266
Journal: NEFROLOGIA
Year: 2022
Reference: Nefrologia. 2022 Nov-Dec;42(6):733-736. doi: 10.1016/j.nefro.2021.04.004. Epub 2021 May 27.
Impact factor:
Publication type: Letter whit IF
Authors: Azancot, Maria; Azancot, Maria; Castaneda, Zaira; Leon-Roman, Juan; Ramos, Natalia; Soler, Maria Jose; Toapanta, Nestor; Zuniga, Jose et al.
DOI: 10.1016/j.nefro.2021.04.004

Publications

Publications searcher

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study.

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.

Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study.

Safety of Obtaining an Extra Biobank Kidney Biopsy Core.

Safety of Obtaining an Extra Biobank Kidney Biopsy Core.

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial.

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, dose escalation study.

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, dose escalation study.

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study.

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study.

Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine.

Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.

Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks.

Salvage hip replacement after cut-out failure of cephalomedullary nail fixation for proximal femur fractures: a case series describing the technique and results.

Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights.

SARS CoV-2 seropositivity in haemodialysis patients.

[SARS CoV-2 seropositivity in hemodialysis patients].

Patronage:

Collaborating:

Accreditations: